When 11-year-old Leo from Cardiff was found to have early-stage type 1 diabetes during a routine screening, his family braced for the relentless cycle of insulin injections, blood sugar checks, and constant vigilance. But now, thanks to a groundbreaking new treatment, Leo and thousands like him across England and Wales will have years—potentially up to three—before those demands begin. Teplizumab, the world’s first therapy proven to delay the onset of symptomatic type 1 diabetes, has been approved for NHS use in children aged 8 and over, as well as adults, marking what experts are calling the most significant breakthrough in diabetes care since insulin was discovered in 1922. Unlike insulin, which replaces a missing hormone, teplizumab targets the root cause: an immune system mistakenly attacking insulin-producing cells in the pancreas. Administered as a daily 30-minute intravenous infusion over 14 consecutive days, the immunotherapy reprograms the body’s defenses, effectively hitting pause on the disease’s progression. The approval by the National Institute for Health and Care Excellence (Nice) is not just a medical milestone—it’s a lifeline for families facing the emotional and physical toll of a chronic condition that typically emerges in childhood. For children, those extra years could mean reaching adolescence, mastering school, or simply enjoying carefree summers without the burden of constant medical management. "Today’s landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment," said Dr Elizabeth Robertson of Diabetes UK. Sanofi, the manufacturer of the drug marketed as Tzield, has secured a confidential discounted pricing agreement with NHS England, ensuring access without straining public funds. While teplizumab is not a cure, its ability to delay symptomatic disease offers a powerful shift—from managing illness to preventing it. The focus now turns to expanding early detection, so more children can benefit. As Helen Knight of Nice put it, this is about giving people "precious extra time"—time that, for a child, could shape a lifetime.